Get back to doing the things you love, faster & without surgery.Receive a Regenexx® Patient Info Packet by Email
Autologous Sameday Procedures
100% Orthopedic Procedures Only
Extensive Clinical Studies & Research
Regenexx® Stem Cell & Platelet Rich Plasma Procedures are the world’s most advanced regenerative injection treatments for treating arthritis, overuse conditions such as tennis elbow or golfer’s elbow, and other conditions that cause elbow pain.
Commonly Treated Elbow Conditions
This is not a complete list, so please contact us or complete the Regenexx Candidate Form if you have questions about whether you or your condition can be treated with these non-surgical procedures.
- Lateral Epicondylitis – Also known as Tennis Elbow
- Medial Epicondylitis – Also known as Golfer’s Elbow
- Nerve entrapment (ulnar nerve)
Regenexx Procedure Safety Data
The information below applies to our safety data on stem cell procedures. Most elbow conditions are treated with platelet rich plasma, which is a far less complex treatment than our stem cell procedure, which requires a bone marrow draw as part of the process (and also includes a platelet rich plasma post-injection).
Stem Cell Procedure SafetyView Stem Cell Procedure Safety
Regenexx has published more data on stem cell safety in peer reviewed medical research for orthopedic applications than any other group world-wide. This is a report of 1,591 patients and 1,949 procedures treated with the Regenexx Stem Cell Procedure. Based on our analysis of this treatment registry data, the Regenexx Stem Cell Procedure is about as safe as any typical injection procedure, which is consistent with what we see every day in the clinic.
More than 104,250 Regenexx® Procedures have been performed since Regenexx pioneered orthopedic stem cell treatments in 2005. Regenexx Procedures are the most advanced orthopedic stem cell procedures in the world.
The published research on Regenexx procedures accounts for approx. 44% of the world’s orthopedic stem cell literature (cumulative n of patients published & treated with bone marrow stem cells as of 1/1/2019)